Royal Bank of Canada’s Elicio Therapeutics ELTX Stock Holding History

Royal Bank of Canada’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Buy	443 +420	+1,826%	+$4.22K	﹤0.01%	7121
2026 Q1	$0	Sell	23 -196	-89%	-$1.89K	﹤0.01%	7271
2025 Q4	$2K	Buy	+219	New	+$1.99K	﹤0.01%	6896
2025 Q2	–	Sell	-36,537	Closed	-$225K	–	7102
2025 Q1	$225K	Buy	+36,537	New	+$283K	﹤0.01%	4609
2024 Q1	–	Sell	-78	Closed	-$1K	–	7151
2023 Q4	$1K	Buy	78 +21	+37%	+$137	﹤0.01%	6915
2023 Q3	$0	Buy	+57	New	+$543	﹤0.01%	7199
2022 Q4	–	Sell	-46	Closed	–	–	7341
2022 Q3	$0	Buy	46 +30	+188%	+$313	﹤0.01%	7541
2022 Q2	$0	Sell	16 -118	-88%	-$1.89K	﹤0.01%	7454
2022 Q1	$3K	Sell	134 -406	-75%	-$9.17K	﹤0.01%	7380
2021 Q4	$15K	Buy	540 +271	+101%	+$13.7K	﹤0.01%	6908
2021 Q3	$26K	Buy	269 +229	+573%	+$24.7K	﹤0.01%	6544
2021 Q2	$5K	Sell	40 -16	-29%	-$2.31K	﹤0.01%	7065
2021 Q1	$10K	Buy	+56	New	+$10.8K	﹤0.01%	6803

Other funds holding ELTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada's ELTX Position: Q2 2026 in Review

Royal Bank of Canada increased its Elicio Therapeutics (ELTX) stake by 1,826% in Q2 2026, buying an estimated $4.22K and bringing the position to 443 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #7121.

Royal Bank of Canada first reported a position in ELTX in Q1 2021 and has held it in 13 quarters since. The position peaked at $225K in Q1 2025. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Royal Bank of Canada held 443 shares of Elicio Therapeutics worth $2K as of Q2 2026.
Royal Bank of Canada bought 420 Elicio Therapeutics shares in Q2 2026, an estimated $4.22K.
Elicio Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7121 holding.
Royal Bank of Canada first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 13 quarters since.
Royal Bank of Canada's Elicio Therapeutics position peaked at $225K in Q1 2025.
46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.